Metsera, INC 10-Q quarterly reports

Metsera reports significant losses and increased R&D expenses in Q3 2025, while its $10 billion acquisition by Pfizer progresses, despite ongoing shareholder and antitrust litigation.

Metsera, a clinical-stage biotechnology company, reported increased operating losses driven by significant research and development investments in its obesity and metabolic disease pipeline, while maintaining a robust cash balance following its recent initial public offering.

Metsera, a clinical-stage biopharmaceutical company, announces its first quarter 2025 financial results, emphasizing progress in its clinical programs for obesity and metabolic diseases.